Access Avalere’s Latest Research on Brand-Name Prescription Drug Spending

  • This page as PDF


Avalere released its latest report today, which highlights current brand-name prescription drug spending and projections for federal healthcare programs (Medicare, Medicaid, TRICARE and VA).
Please note: This is an archived post. Some of the information and data discussed in this article may be out of date. It is preserved here for historical reference but should not be used as the basis for business decisions. Please see our main Insights section for more recent posts.

Using data from the Medicare Trustees Report, the National Health Expenditures Accounts, CMS and other sources, it’s estimated that brand-name prescription drug manufacturers will receive about $1,126 billion in revenues from the sale of outpatient prescription medicines to federal healthcare beneficiaries between 2015 and 2024. {embed=”embeds/_article_slideshow” group_name=”FederalSpending1″}

Overall, it’s expected that the federal government will spend $13.7 trillion on healthcare in the next 10 years (not including subsidies provided to enrollees in Marketplace plans). The $1,126 billion going towards outpatient prescription medicines makes up 9 percent of the total spend in comparison to other categories mentioned in the figure below.

{embed=”embeds/_article_slideshow” group_name=”FederalSpending 2″}

Download the full report for additional findings.

Webinar | A Closer Look at Patient Support Avalere experts explored how potential implications of the Inflation Reduction Act (IRA)’s out-of-pocket cap, in addition to other key regulatory and policy activities shaping benefit design and patient cost-share (e.g., EHB), could impact patient commercial and foundation assistance. Learn More
Watch Now

Sign up to receive more insights about
Please enter your email address to be notified when new insights are published.

Back To Top